{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"4.9","value":"84.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"}],"units":"Participants"}],"title":"Baseline (Day 0)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"7.8","value":"81"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"}],"units":"Participants"}],"title":"Cycle 1 Week 1 (approximately 1 week from baseline)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"9.3","value":"70.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"}],"units":"Participants"}],"title":"Cycle 1 Week 2 (approximately 2 weeks from baseline)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.71","value":"73.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"}],"units":"Participants"}],"title":"Cycle 1 Week 3 (approximately 3 weeks from baseline)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"6.8","value":"76.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"}],"units":"Participants"}],"title":"Cycle 1 Week 4 (approximately 4 weeks from baseline)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"5.5","value":"85.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"}],"units":"Participants"}],"title":"Cycle 2 Week 1 (approximately 5 weeks from baseline)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"13.7","value":"62.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"}],"units":"Participants"}],"title":"Cycle 2 Week 2 (approximately 6 weeks from baseline)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"9.3","value":"72"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"}],"units":"Participants"}],"title":"Cycle 2 Week 3 (approximately 7 weeks from baseline)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"8.5","value":"76.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"}],"units":"Participants"}],"title":"Cycle 2 Week 4 (approximately 8 weeks from baseline)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":".71","value":"82.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"}],"units":"Participants"}],"title":"Cycle 3 Week 1 (approximately 9 weeks from baseline)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"24.3","value":"54.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"}],"units":"Participants"}],"title":"Cycle 3 Week 2 (approximately 10 weeks from baseline)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.8","value":"74.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"}],"units":"Participants"}],"title":"Cycle 3 Week 3 (approximately 11 weeks from baseline)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"12.4","value":"72.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"}],"units":"Participants"}],"title":"Cycle 4 Week 1 (approximately 12 weeks from baseline)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"12.4","value":"59.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"}],"units":"Participants"}],"title":"Cycle 4 Week 2 (approximately 13 weeks from baseline)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"5.5","value":"76"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"}],"units":"Participants"}],"title":"Cycle 4 Week 3 (approximately 14 weeks from baseline)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"11.7","value":"76.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"}],"units":"Participants"}],"title":"Cycle 4 Week 4 (approximately 15 weeks from baseline)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.5","value":"85.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"}],"units":"Participants"}],"title":"End of Treatment (up to 180 days from baseline)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"}],"units":"Participants"}],"description":"The degree of DNA methylation at CpG sites within the promoter of the tumor antigen NY-ESO-1 was quantified. Results are reported as the percentage of methylated cytosines relative to the total cytosines at the analyzed CpG sites.","dispersionType":"Standard Deviation","groups":[{"description":"Patients receive DEC-205/NY-ESO-1 fusion protein CDX-1401 intracutaneously and poly ICLC SC on day -14, on day 15 of courses 1-4, and then on day 1 of every 4 courses thereafter. Patients also receive nivolumab IV over 30 minutes on days 1 and 15 and decitabine IV over 1 hour on days 1-5. Courses with nivolumab and decitabine repeat every 4 weeks in the absence of disease progression or unaccepted toxicity.\n\nDEC-205/NY-ESO-1 Fusion Protein CDX-1401: Given intracutaneously\n\nDecitabine: Given IV\n\nLaboratory Biomarker Analysis: Correlative studies\n\nNivolumab: Given IV\n\nPoly ICLC: Given SC\n\nThe study originally provided for the possibility of dose de-escalation for the treatment arms, but as we had no dose limiting toxicities, the dose level 1 was declared the maximum administered dose and all patients were enrolled and treated at dose level 1.","id":"OG000","title":"Treatment (CDX-1401, Poly ICLC, Decitabine, Nivolumab)"}],"paramType":"MEAN","populationDescription":"All treated and eligible patients","reportingStatus":"POSTED","timeFrame":"Cycle 1- 4 weekly to EOT (up to 180 days from baseline)","title":"Peripheral Blood and Bone Marrow Cells Responses","type":"SECONDARY","unitOfMeasure":"percentage of methylated cytosines"}